Press releases

Stockholm, July 23, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that two real-world evidence (RWE) posters have been accepted for presentation at the upcoming International Myeloma Society (IMS) Annual Meeting, taking place in Toronto, Canada on September 17-20

Stockholm, July 9, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the net sales for the second quarter of 2025

Stockholm, July 8, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that its drug Pepaxti has been included in new clinical practice guidelines from EHA-EMN* for patients with relapsed, refractory multiple myeloma. This marks an important recognition by leading experts of the drug’s clinical value and ability to meet an unmet medical need in the treatment of this serious blood cancer

Stockholm, Sweden – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 22 May 2025. At the Annual General Meeting, the following principal resolutions were passed

Stockholm, May 20, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the first patient has been enrolled in its new real-world evidence study, evaluating the use of Pepaxti in routine clinical settings across Spain

Stockholm – May 15, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the first quarter 2025

Stockholm – May 13, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the first quarter 2025, at 08:00 CET on May 15, 2025

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the 2024 Annual Report has been published

Stockholm, April 16, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of new real-world data that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM). The data were presented in an abstract from the University of Catania, Italy. It highlights treatment outcomes in a single-center real-world setting

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m. Registration for attendees will commence at 09.30 a.m